Exploratory Study on mRNA Therapy Targeting CD19 for the Treatment of Refractory Autoimmune Diseases

NCT07362758 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Autoimmune Diseases

Interventions

DRUG: in vivo CAR-T drug based on LNP-mRNA

Sponsor

Xinqiao Hospital of Chongqing